Xtant Medical Hldgs Stock Price To Earning
XMS Stock | EUR 0.34 0.01 3.03% |
XTANT MEDICAL HLDGS fundamentals help investors to digest information that contributes to XTANT MEDICAL's financial success or failures. It also enables traders to predict the movement of XTANT Stock. The fundamental analysis module provides a way to measure XTANT MEDICAL's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XTANT MEDICAL stock.
XTANT |
XTANT MEDICAL HLDGS Company Price To Earning Analysis
XTANT MEDICAL's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition |
Based on the latest financial disclosure, XTANT MEDICAL HLDGS has a Price To Earning of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Medical Devices industry. The price to earning for all Germany stocks is 100.0% higher than that of the company.
Did you try this?
Run Top Crypto Exchanges Now
Top Crypto ExchangesSearch and analyze digital assets across top global cryptocurrency exchanges |
All Next | Launch Module |
XTANT Fundamentals
Return On Equity | -0.26 | |||
Return On Asset | -0.0619 | |||
Profit Margin | (0.15) % | |||
Operating Margin | (0.1) % | |||
Shares Outstanding | 108.66 M | |||
Shares Owned By Insiders | 7.59 % | |||
Shares Owned By Institutions | 75.17 % | |||
Revenue | 56.67 M | |||
Gross Profit | 32.49 M | |||
EBITDA | (4.28 M) | |||
Net Income | (2.83 M) | |||
Cash And Equivalents | 20.31 M | |||
Cash Per Share | 0.23 X | |||
Total Debt | 17.43 M | |||
Debt To Equity | 0.51 % | |||
Current Ratio | 3.83 X | |||
Book Value Per Share | 0.32 X | |||
Cash Flow From Operations | 1.79 M | |||
Earnings Per Share | (0.08) X | |||
Number Of Employees | 116 | |||
Beta | 0.63 | |||
Market Capitalization | 72.54 M | |||
Z Score | 2.4 |
About XTANT MEDICAL Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XTANT MEDICAL HLDGS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XTANT MEDICAL using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XTANT MEDICAL HLDGS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in XTANT Stock
XTANT MEDICAL financial ratios help investors to determine whether XTANT Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in XTANT with respect to the benefits of owning XTANT MEDICAL security.